Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 6/20 | 0.34 |
| ▸ | DRD2 | P14416 | 6/20 | 0.34 |
| ▸ | HTR2A | P28223 | 6/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792242 | 0.85 | ACHE (0.38) | ACHEDRD2ADRA1DDRD3NR1I2 | |
| SCHEMBL804226 | 0.83 | PRKCA (0.31) | — | |
| SCHEMBL14606912 | 0.83 | NR1I2 (0.40) | KCNH2ESR1NR1I2SCN9A | |
| SCHEMBL12510266 | 0.81 | SCN9A (0.32) | HRH3HRH1KCNH2ESR1SCN9A | |
| SCHEMBL14572865 | 0.81 | USP14 (0.36) | ACHEHRH3ESR1NR1I2SCN9A | |
| SCHEMBL792449 | 0.81 | ACHE (0.35) | ACHEHTR1ADRD2HTR2AHRH3 | |
| SCHEMBL803814 | 0.81 | PRKCA (0.42) | ACHEHTR2ANR1I2SCN9ACCR3 | |
| SCHEMBL803861 | 0.80 | SCN9A (0.30) | SCN9A | |
| SCHEMBL10283718 | 0.76 | CYP2D6 (0.34) | HRH1NR1I2SCN9A | |
| SCHEMBL803984 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | ACHE 3981/4885HTR1A 4866/4885DRD2 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.